in search of more: cur ious minds that thrive on collaboration.

About Us

Over the last two decades, Sun Pharma has established itself as a leading player in the generics market in the U.S. We have become the eighth-largest generics pharmaceutical company in the U.S. and are ranked second by prescriptions in the U.S. dermatology market. We are rapidly ramping up our presence in the specialty branded market, with dermatology, ophthalmology, and oncology as key target segments. Today, our U.S. business makes up 30% of our global revenue and we’re continuing to invest in our people and our shared success.

How We Work

At Sun Pharma, we have found strength in our diversity, imbued by our culture of mutual respect, empathy, and adhering to the highest ethical standards. Our approach and culture are represented through Sunology: the Sun Pharma way of life.

Key Milestones

1998

Entered the U.S. market through the acquisition of Caraco Pharmaceutical Laboratories

2010

Acquired Taro Pharmaceuticals to enter dermatology market

2013

Acquired DUSA Pharmaceuticals, entering the branded specialty market

2015

Acquired Ranbaxy Laboratories, expanding generics portfolio

2016

Acquired 14 brands from Novartis to expand our portfolio in Japan, a key pharmaceutical market. Acquired Ocular Technologies Sarl to strengthen our branded ophthalmic offerings. Acquired Biosintez to boost our footprint in Russia. Launched our first U.S. branded ophthalmic product, BromSite™.

2017

Acquired Odomzo®, a breakthrough therapy for advanced skin cancer, marking Sun Pharma’s entry into branded oncology.

2018

Launched specialty product, ILUMYA™ in the United States for treatment of moderate-to-severe plaque psoriasis

2019

Acquired Pola Pharma to strengthen our dermatology presence in Japan, launched Cequa® in the U.S. for dry eye treatment, and expanded into Greater China through a strategic partnership with China Medical System.

2020

Marked 25 years since our debut on the Indian Stock Exchanges and launched ILUMYA™ in Japan for the treatment of plaque psoriasis.

2021

Launched ILUMYA™ in Canada for plaque psoriasis, introduced WINLEVI® in the U.S. for acne treatment, and entered India’s nutrition space with Revital NXT, the country’s first ginseng-based nutrition bar.

2022

Acquired the Uractiv® portfolio from Fiterman Pharma to strengthen our consumer healthcare presence in Romania.

2023

Acquired Concert Pharmaceuticals to enhance our innovative specialty drug pipeline in the USA.

2024

Sun pharma included in S&P global sustainability notebook

2025

Completed acquisition of Taro Pharmaceutical to expand our dermatology and generics portfolio, and acquired Checkpoint Therapeutics to enter the cutaneous oncology market.

Vision

We’re reaching people and touching lives globally as a leading provider of valued medicines.

Our Values

Sunology, a combination of Sun and Ideology, is the way of life at Sun Pharma. We practice humility, integrity, passion, and innovation.

Jobs for You

Technician - I Brampton, Ontario
Apprentice, Plant Maintenance Brampton, Ontario
Territory Manager, Medical Dermatology - Eastern Canada (New Brunswick/Nova Scotia/PEI/Newfoundland) Halifax, Nova Scotia

You have no recently viewed jobs.

You have no saved jobs.